Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 8/20 | 0.63 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.60 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | TK2 | O00142 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL15201232 | 1.00 | DNMT1 (0.63) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL231959 | 0.95 | DNMT1 (0.64) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL22299584 | 0.95 | DNMT1 (0.64) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL29431942 | 0.95 | DNMT1 (0.64) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL25837386 | 0.95 | DNMT1 (0.64) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL231960 | 0.95 | DNMT1 (0.64) | DNMT1DNMT3BADRB1FPR2TK2 | |
| Pyrophosphoric Acid SCHEMBL14660971 | 0.95 | DNMT1 (0.60) | DNMT1DNMT3BADRB1FPR2TK2 | |
| Triphosphate SCHEMBL28135309 | 0.93 | DNMT1 (0.58) | DNMT1DNMT3BADRB1FPR2 | |
| SCHEMBL17204628 | 0.91 | DNMT1 (0.60) | DNMT1DNMT3BADRB1FPR2TK2 | |
| SCHEMBL1331043 | 0.88 | TYMS (0.55) | DNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | KARIUS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12553085-B2 | Sequencing kit | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | UNIV OXFORD INNOVATION LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260028379-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4665753-A1 | ARMOURED REGULATORY T CELL | King's College London (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361502-A1 | Promoters And Compositions | UNIV OXFORD INNOVATION LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| EP-3802877-B1 | METHOD | OXFORD NANOPORE TECH PLC (GB) | 2025-11-05 | — | — | EP | disclosed |
| WO-2014102539-A1 | DELIVERY METHOD USING MESOPOROUS SILICA NANOPARTICLES | ISIS INNOVATION LIMITED (GB) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014072703-A1 | QUADRUPLEX METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013153359-A1 | MUTANT LYSENIN PORES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013121201-A1 | APTAMER METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-08-22 | — | — | WO | disclosed |
| EP-0923591-A4 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX INC (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-0923591-A1 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5876938-A | Use of boron-containing polynucleotides as diagnostic agents | PROLINX, INCORPORATED (US) | 1999-03-02 | — | — | US | disclosed |
| US-5831045-A | Boronic acid-containing polynucleotides | PORLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| US-5831046-A | Boronic acid-contaning nucleic acid monomers | PROLINX, INCORPORATED (US) | 1998-11-03 | — | — | US | disclosed |
| WO-1998005672-A1 | NOVEL BORONIC ACID-CONTAINING NUCLEIC ACIDS AND THEIR USE AS DIAGNOSTIC AGENTS | PROLINX INCORPORATED (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | NUP210, EPCAM, PHAX | ADRB1 4010/4885DNMT1 2398/4885DNMT3B 2061/4885 |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | DNA2, MTREX, DDX21 | ADRB1 4774/4885DNMT1 123/4885DNMT3B 154/4885 |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | DDX6, DDX1, DDB1 | ADRB1 4608/4885DNMT1 679/4885DNMT3B 735/4885 |
| US-12553085-B2 | Sequencing kit | PHAX, TIA1, POLM | ADRB1 4270/4885DNMT1 1190/4885DNMT3B 838/4885 |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | POLRMT, PITPNB, NUP205 | ADRB1 4063/4885DNMT1 959/4885DNMT3B 1043/4885 |
| US-20260028379-A1 | MUTANT PORE | PTMS, NUP50, NUP205 | ADRB1 4612/4885DNMT1 2912/4885DNMT3B 1770/4885 |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | SPOUT1, NOP2, METTL16 | ADRB1 4785/4885DNMT1 818/4885DNMT3B 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.